华兰生物: 监事会决议公告

Core Viewpoint - The supervisory board of Hualan Biological Engineering Co., Ltd. held its 15th meeting of the 8th session, approving several key proposals including the annual report, profit distribution plan, and changes in accounting policies, all of which will be submitted for shareholder approval at the upcoming annual general meeting [1][2][3]. Meeting Overview - The meeting was held on March 28, 2025, with all three supervisory board members present, complying with legal and regulatory requirements [1]. Resolutions Passed - The supervisory board approved the 2024 Annual Work Report, which will be submitted for shareholder review [2]. - The 2024 Annual Report and its summary were also approved, confirming that the report accurately reflects the company's situation without any misleading statements [2]. - The 2024 Financial Settlement Report was approved, pending shareholder approval [2]. - A profit distribution plan was approved, proposing a cash dividend of 2 yuan per 10 shares, totaling approximately 365.76 million yuan, with remaining undistributed profits rolling over to the next year [2][3]. - Changes to accounting policies and estimates were approved, ensuring compliance with the latest accounting standards without significantly impacting the company's financial status [3][4]. - The 2024 Internal Control Self-Evaluation Report was approved, indicating a robust internal control system in place [4]. - The proposal to use idle funds for investment and financial management was approved, aimed at improving fund utilization efficiency [5]. - The reappointment of the auditing firm for 2025 was approved, pending shareholder approval [5]. - The proposal to repurchase and cancel certain restricted stock options from the 2023 incentive plan was approved, ensuring compliance with relevant regulations [6]. - A proposal to amend the company's registered capital and related articles in the Articles of Association was approved, pending shareholder approval [6][7]. - The establishment of a Public Opinion Management System and a Market Value Management System was approved [7].